Patented drugs had a share of some 52 percent of drug costs in select public Canadian drug plans. This statistic depicts the distribution of drug costs by drug type in select Canadian public drug plans in Canada as of fiscal year 2021/2022.
Distribution of drug costs by drug type in select public Canadian drug plans in 2021/2022
This analysis only includes data for beneficiaries that met their deductible and received public reimbursement.
Direct-acting antiviral (DAA) drugs are used in the treatment of hepatitis C.
High-cost drugs have an average annual treatment cost of greater than $10,000 and include both biologics and non-biologics.
Included are: British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, New Brunswick, Nova Scotia, Prince Edward Island,
Newfoundland and Labrador, and Yukon.
* The patented medicines market segment includes all medicines that had patent protect at some time during in the period of study, even
if the patent expired during that period. As such, the rate of growth does not reflect the loss of patent exclusivity for some top-selling
medicines over the course of the fiscal year.
** This market segment includes devices, compounded drugs, and other products that are reimbursed by public drug plans
but do not have a Health Canada assigned Drug Identification Number (DIN).
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
PMPRB. (December 12, 2023). Distribution of drug costs by drug type in select public Canadian drug plans in 2021/2022 [Graph]. In Statista. Retrieved December 22, 2024, from https://www.statista.com/statistics/711938/drug-cost-distribution-in-public-drug-plans-by-drug-type-in-canada/
PMPRB. "Distribution of drug costs by drug type in select public Canadian drug plans in 2021/2022." Chart. December 12, 2023. Statista. Accessed December 22, 2024. https://www.statista.com/statistics/711938/drug-cost-distribution-in-public-drug-plans-by-drug-type-in-canada/
PMPRB. (2023). Distribution of drug costs by drug type in select public Canadian drug plans in 2021/2022. Statista. Statista Inc.. Accessed: December 22, 2024. https://www.statista.com/statistics/711938/drug-cost-distribution-in-public-drug-plans-by-drug-type-in-canada/
PMPRB. "Distribution of Drug Costs by Drug Type in Select Public Canadian Drug Plans in 2021/2022." Statista, Statista Inc., 12 Dec 2023, https://www.statista.com/statistics/711938/drug-cost-distribution-in-public-drug-plans-by-drug-type-in-canada/
PMPRB, Distribution of drug costs by drug type in select public Canadian drug plans in 2021/2022 Statista, https://www.statista.com/statistics/711938/drug-cost-distribution-in-public-drug-plans-by-drug-type-in-canada/ (last visited December 22, 2024)
Distribution of drug costs by drug type in select public Canadian drug plans in 2021/2022 [Graph], PMPRB, December 12, 2023. [Online]. Available: https://www.statista.com/statistics/711938/drug-cost-distribution-in-public-drug-plans-by-drug-type-in-canada/
